United States & AstraZeneca
29 shared events · Importance 9 · Last updated Aug 14, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
United States: The US stands to gain from increased investment and manufacturing, aligning with the Trump administration's priorities. The deal would likely require US regulatory approval.
AstraZeneca: AstraZeneca is the initiator of the merger talks, seeking to expand its US presence. Its shares fell over 7% on the news, reflecting investor skepticism about the deal's value and execution risk.
Aug 02, 2026 · 60 articles
Business
United States: Zegfrovy is approved in the US; FDA granted Breakthrough Therapy Designation for first-line use.
AstraZeneca: AstraZeneca expands its lung cancer portfolio with a novel oral EGFR inhibitor, complementing existing drugs like Tagrisso. The deal involves a $600M upfront payment and potential milestones, but does not affect 2026 guidance.
Jul 14, 2026 · 8 articles
Domestic
United States: The United States economy faces uncertainty due to new tariffs, with potential for higher inflation, dampened hiring, and increased costs for consumers and businesses.
AstraZeneca: AstraZeneca, among other pharmaceutical companies, had previously announced investments in U.S. production due to the threat of tariffs, but the new, higher tariffs introduce further uncertainty.
Sep 26, 2025 · 7 articles
Business
United States: Engaged in conflict with Iran, impacting oil prices and markets. Also intervened in yen markets.
AstraZeneca: Investors punished the stock over merger talks with Bristol Myers Squibb.
Jul 14, 2026 · 280 articles
Regulatory
United States: The U.S. gains a new flu vaccine option, potentially improving public health outcomes for older adults.
AstraZeneca: AstraZeneca's flu vaccine portfolio could be affected by the entry of mFLUSIVA.
Aug 05, 2026 · 105 articles
Accidents
United States: Major donor and also imposed travel restrictions on travelers from DRC, which could hinder aid delivery. Its policies have mixed effects on the response.
AstraZeneca: Its COVID-19 vaccine technology is used in the Oxford candidate, but AstraZeneca itself is not directly involved in the Ebola response.
Mar 09, 2018 · 543 articles
Accidents
United States: The United States>>> has pledged financial aid and is monitoring the Ebola outbreak, with some of its citizens exposed or infected, but its previous aid cuts and withdrawal from the World Health Organization>>> have been criticized for weakening global health response capacity.
AstraZeneca: AstraZeneca was involved in the development of the COVID-19 vaccine platform that is now being considered for a Bundibugyo ebolavirus vaccine, showcasing its role in vaccine innovation.
May 18, 2026 · 505 articles
Business
United States: The United States is mentioned as the regulator that rejected AstraZeneca's breast cancer drug camizestrant, part of the series of setbacks. This regulatory action affects AstraZeneca's US market prospects.
AstraZeneca: AstraZeneca is the central company, facing another pipeline setback with the discontinuation of the volrustomig trial. Despite this, it reported positive results from other trials and reaffirmed its 2030 revenue target, with shares rising slightly.
Aug 17, 2026 · 20 articles
Regulatory
United States: The US is the target market for the generic Olaparib, with a $1.4B opportunity. The event reflects the US generic drug market dynamics.
AstraZeneca: AstraZeneca's Lynparza faces generic competition if the tentative approval leads to final launch. The ongoing Paragraph IV litigation may delay market entry.
Jul 19, 2026 · 6 articles
International
United States: The US paused its bombing campaign after 13 nights, citing diplomatic space, but maintains a naval blockade and retains military options. The pause has eased oil prices but raised questions about strategy and munitions stockpiles.
AstraZeneca: AstraZeneca gained 1.3% after topping Q2 profit expectations.
Jul 08, 2026 · 472 articles
International
United States: US enforces naval blockade and claims control; seeks to reopen strait but faces domestic pressure over high fuel prices.
AstraZeneca: Pharmaceutical company, whose stock gained on higher oil prices.
Jul 28, 2026 · 318 articles
Tech
United States: The United States is mentioned in the context of pancreatic cancer mortality projections and orphan drug designations, indicating a relevant market and regulatory environment.
AstraZeneca: AstraZeneca is collaborating on the DURIPANC study, providing its drug Imfinzi, and stands to benefit from the success of the combination therapy.
Jun 01, 2026 · 10 articles
Business
United States: The U.S. is a key market where Alvogen and Lotus will commercialize the biosimilars, with Alvogen retaining direct commercialization rights.
AstraZeneca: AstraZeneca's Imfinzi faces potential biosimilar competition, which could erode its market share, though the impact is long-term and uncertain.
Aug 21, 2026 · 6 articles
Domestic
United States: The US has shifted toward a risk-based approach; Health Secretary Robert F. Kennedy Jr. has advocated stopping recommendations for children.
AstraZeneca: AstraZeneca's vaccine was previously suspended for under 60s in Germany in 2021 due to blood clot concerns; not directly affected by current policy.
Jul 13, 2026 · 6 articles
Business
United States: The United States is the home country of both companies and the regulatory environment, with the acquisition supporting domestic supply chain and technology leadership.
AstraZeneca: AstraZeneca is mentioned as a customer and partner of IonQ, but the acquisition does not directly affect it.
Jul 28, 2026 · 6 articles
Business
United States: The United States is the region where Roche and Nurix Therapeutics, Inc. will equally split profits and losses from the commercialization of bexobrutideg.
AstraZeneca: AstraZeneca is mentioned as a developer of an approved BTK inhibitor, Calquence, which is a competitor to bexobrutideg.
Jun 07, 2026 · 22 articles
Business
United States: The United States is the primary market for Lantheus' products and the regulatory jurisdiction for the deal, with potential antitrust review.
AstraZeneca: AstraZeneca is mentioned as a prior acquirer of KC Pharmaceuticals, illustrating sector M&A activity.
Aug 03, 2026 · 7 articles
Business
United States: Regulatory jurisdiction where FDA designations were granted and where commercialization rights are included.
AstraZeneca: Collaborator with Innate on monalizumab, mentioned as part of Innate's partnered assets, not directly affected by this deal.
Aug 10, 2026 · 10 articles
Business
United States: Ascentage Pharma has a U.S. presence and FDA clearances, but this event does not directly impact the country.
AstraZeneca: AstraZeneca is a partner of Ascentage Pharma, but this event does not directly involve AstraZeneca.
Jul 26, 2026 · 6 articles
Tech
AstraZeneca: AstraZeneca has partnered with Quell Therapeutics to develop therapies for inflammatory bowel disease, indicating its interest in the field of immune tolerance.
Oct 06, 2025 · 6 articles
Regulatory
AstraZeneca: AstraZeneca, like Pfizer, previously agreed to lower prescription drug costs for United States — Medicaid, contributing to the broader context of the Trump administration's efforts to control drug prices.
Nov 06, 2025 · 6 articles
International
AstraZeneca: AstraZeneca announced a significant investment of $15 billion in China through 2030 to expand its medicines manufacturing and research, demonstrating confidence in the Chinese market.
Jan 30, 2026 · 9 articles
International
AstraZeneca: AstraZeneca's CEO, Pascal Soriot, is part of the business delegation, suggesting potential for increased pharmaceutical and healthcare sector cooperation with China.
Jan 27, 2026 · 34 articles
Regulatory
AstraZeneca: AstraZeneca is mentioned as a collaborator with Innate Pharma, specifically on the monalizumab antibody.
Apr 02, 2026 · 7 articles
Regulatory
AstraZeneca: AstraZeneca is mentioned as a biopharmaceutical company with whom Innate Pharma has established collaborations, including the development of monalizumab.
Apr 13, 2026 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how United States and AstraZeneca interact across events, view sentiment trends, and discover connected entities.
Open Dashboard